NovaBridge Biosciences (NBP) Research & Development (2019 - 2025)

NovaBridge Biosciences (NBP) has reported Research & Development for 6 consecutive years, with $55.7 million the latest figure, recorded in Q4 2025.

• Quarterly Research & Development rose 823.02% year-over-year to $55.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $62.9 million (up 747.84% YoY) and the FY2025 annual result came in at $62.9 million, up 188.95% from the prior year.
• Research & Development rose to $55.7 million in Q4 2025 per NBP's latest filing, from $11.3 million in the prior quarter.
• Over the last five years, Research & Development for NBP reached as high as $55.7 million in Q4 2025 and fell as low as -$143.1 million in Q4 2022.
• A 4-year average of -$5.4 million and a median of -$3.8 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development tumbled 82.64% — and 2025, when it surged 823.02%.
• Year by year, Research & Development stood at -$143.1 million in 2022, then soared by 124.27% to $34.7 million in 2023, then slumped by 82.64% to $6.0 million in 2024, then jumped by 823.02% to $55.7 million in 2025.
• According to Business Quant data, Research & Development over the past three periods registered $55.7 million, $11.3 million, and -$3.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.